Marksans Pharma has informed that (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its product Exemestane 25mg film-coated tablets from UK MHRA.
The above information is a part of company’s filings submitted to BSE.